Hims & Hers Health Inc. Health platform Hims & Hers Health Inc. announced Monday that it's rolling out injectable weight-loss drugs that cost a fraction of the price of competitors Wegovy and Ozempic. Hims & Hers says its GLP-1 medications contain the same active ingredients as its rivals, but the price starts at $199 per month. For comparison, Wegovy costs around $1,350 per month, and Ozempic is priced at around $935 without insurance. Novo Nordisk produces both drugs. "We've leveraged our size and scale t ...

减肥药物市场 - Hims & Hers公司宣布计划提供含有与热门减肥药物Ozempic和Mounjaro相同活性成分的GLP-1注射剂后，公司股价大涨[1] - 热门减肥药物需求推动了Eli Lilly和Novo Nordisk等制造商的收入和股价[2] - 减肥和糖尿病治疗市场由于公司过去一年急于增加生产而受到供应限制[3] Hims & Hers公司 - Hims & Hers Health公司表示将开始提供GLP-1注射剂作为其减肥药物套餐的一部分，导致公司股价飙升近28%[4]

Topline Shares of telehealth company Hims & Hers Health closed at a three-year high Monday after the company announced a weight-loss treatment starting at $199 a month that will compete with Novo Nordisk's Wegovy and Ozempic and enter the weight-loss market amid a shortage of branded treatments. Get Forbes Breaking News Text Alerts: We're launching text message alerts so you'll always know the biggest stories shaping the day's headlines. Text "Alerts" to (201) 335-0739 or sign up here. Contra Hims announced ...

Hims & Hers Health Inc (NYSE:HIMS) stock is soaring today, up 29.4% to trade at $18.85 and earlier hitting a three-year high of $20.11. Today's pop comes after the healthcare platform added GLP-1 injections to its weight-loss services, a compounded and cheap version of Novo Nordisk's (NVO) semaglutide (the active ingredient in popular weight-loss drug Wegovy). Since the start of the year, HIMS is sporting a 110% lead, with the 100-day moving average stepping up as support earlier this month. Options bulls a ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell- side) analysts often affect a stock's price, do they really matter? Let's take a look at what these Wall Street heavyweights have to say about Hims & Hers Health, Inc. (HIMS) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. Hims & Hers Health curr ...

With the stock market heating up again, consider investing in disruptive stocks to buy. Betting on disruptive stocks, especially at the right prices, can prove incredibly rewarding. Moreover, with expectations of a sustained bull run ahead, you'd be remiss to ignore the three disruptive stock bets at current prices. Disruptive stocks to buy have the potential to revolutionize their respective industries through their innovative prowess. For investors who can see the potential of disruptive stocks, these bus ...

Hims & Hers Health, Inc. (HIMS) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving. The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since ...

Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this company have returned +8.3% over the past month versus the Zacks S&P 500 composite's +2.5% change. The Zacks Medical Info Systems industry, to which Hims & Hers Health belongs, has lost 9.1% over this period. Now the key question is: Where could the stock be headed in the near term? A ...

Key PointsCall option buyers think Starbucks, Pfizer, and Him & Hers Health stocks could see higher prices relatively quickly.All three stocks are offering unjustifiable discounts to their 52-week high prices, becoming targets for options traders. Analysts see at least a double-digit upside through their price targets today, backing these traders up.Options are complicated and not for the faint of heart. While some investors may use them to take on irresponsible leverage levels on their minor positions, oth ...

A six-point argument that shares are a table-pounding opportunity worth scooping up now.Telehealth company Hims & Hers Health (HIMS -4.88%) found itself immersed in controversy recently after some polarizing social media posts by the company's CEO sparked debate. The stock took a bit of a hit as a result Then the company released first-quarter earnings amid the uproar, giving bulls a lot to cheer about.While it's often a bad idea for a company to go anywhere near political discussions, there are enough reas ...